Amifampridine SERB (amifampridine)
Generic
- Region
- 🇪🇺 EU
- Active substance
- amifampridine
- Company
- SERB SA
- Status
- Authorised
- Therapeutic area
- Myasthenia Gravis
- CHMP opinion
- Thu 24 Mar 2022
- EU approval
- Thu 19 May 2022
- Designations
- Generic
- Application
- EMEA/H/C/005839
- ATC
- N07XX05
- Official record
- www.ema.europa.eu
Indication
Symptomatic treatment of Lambert-Eaton myasthenic syndrome (LEMS) in adults.
Regulatory milestones
No milestones recorded in the last year.
Same substance in other markets
- 🇪🇺 Firdapse (previously Zenas) Authorised · SERB SA
Follow Amifampridine SERB
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.